Understanding Medications Post-Bariatric Surgery
Weight loss surgery, such as gastric bypass surgery and sleeve gastrectomy, has proven to be an effective option for individuals looking to lose weight and improve their health. However, understanding the safety and efficacy of medications following these procedures is crucial, especially when patients experience weight regain. This article will explore the use of weight loss drugs like Ozempic, Wegovy(known as semaglutide), and Mounjaro (also known as Tirzepatide) after bariatric surgery and provide recommendations for patients considering these medications.
Bariatric Surgery and Post-Operative Medications Overview
Weight loss surgery options include gastric bypass, gastric banding (lap band), and gastric sleeve (sleeve gastrectomy) procedures. These surgeries alter the digestive system to aid in weight loss and may help in managing type 2 diabetes. Following these surgeries, medications may need to be adjusted, and additional weight loss medications may be prescribed to address weight regain and maintain body weight. Ozempic, Wegovy, and Mounjaro are obesity medications that belong to a class of drugs known as GLP-1 receptor agonists, which were originally developed for blood sugar control and also aid in weight loss.
Ozempic After Gastric Bypass and Gastric Sleeve Surgeries
Ozempic, developed by Novo Nordisk, is generally safe and effective for use after gastric bypass and gastric sleeve procedures. It works as a GLP-1 receptor agonist, stimulating GLP-1 receptors in the body to reduce appetite and improve blood sugar control, which can be particularly beneficial for patients with type 2 diabetes. Another way this medicine works is by slowing down the emptying of your sleeve or bypass. When using these medications, you will probably feel more full with less food and this feeling of fullness will last longer. Common side effects include gastrointestinal issues. When using Ozempic after weight loss surgery, patients should closely monitor their blood sugar levels and discuss any concerns with their healthcare provider.
Wegovy After Gastric Sleeve Surgery
Wegovy, another GLP-1 receptor agonist by Novo Nordisk, is actually the same compound as Ozempic just with different dosing and indications. It has demonstrated safety and effectiveness in promoting weight loss after gastric sleeve procedures. With a dosage of up to 2.4 mg, Wegovy helps in reducing appetite and controlling blood sugar levels, which can be especially helpful for those who gain weight after surgery. Common side effects include gastrointestinal issues. Patients using Wegovy after bariatric surgery should be closely monitored by their healthcare providers for any potential issues.
Tirzepatide’s (Mounjaro) After Bariatric Surgery
Tirzepatide, sold under the brand name Mounjaro, has shown promising results in terms of safety and effectiveness for weight loss after gastric bypass and gastric sleeve surgeries. As a dual GLP-1 and GIP receptor agonist, Tirzepatide helps control appetite and regulate blood sugar levels. Potential side effects include gastrointestinal issues. Patients should discuss the use of Tirzepatide with their healthcare providers and follow any necessary precautions.
Making Informed Decisions About Post-Bariatric Surgery Medications
Ozempic, Wegovy, and Tirzepatide/Mounjaro are promising options for weight loss after bariatric surgery, particularly for those experiencing weight regain. It’s important for patients to understand the safety, efficacy, and potential side effects of these medications, and to consult with their healthcare providers before making any decisions. It is very important to seek expert care from BMI of Texas if you have had weight loss surgery and are considering these medications as they do not react quite the same as they would in non surgical patients. For this reason your primary care may not be able to get the dosing optimized and you may have unintended side effects. By staying informed and following professional guidance, patients can make the best choices for their post-operative weight loss journey.
BMI of Texas offers an extensive, dedicated program that specializes in the care of post-operative weight loss surgery patients. This comprehensive Medical and Surgical Longitudinal Management Program (CMSP) encompasses various facets of health management, including the usage of medications, diet planning, physical activity, mental health support, gut microbiome, and hormone management. Patients who enroll in the CMSP can expect significant improvement in their outcomes, with data showing 15-20% better initial weight loss following surgery, and enhanced long-term success compared to surgery alone. Importantly, the CMSP is not exclusive to those who have undergone surgery at BMI of Texas – we welcome all individuals seeking a comprehensive approach to weight loss and health management. Enroll today and embark on a healthier journey with us.
 American Society for Metabolic and Bariatric Surgery (ASMBS). (n.d.). Types of Bariatric Surgery. Retrieved from https://asmbs.org/patients/bariatric-surgery-procedures
 Mechanick, J.I., Apovian, C., Brethauer, S., et al. (2018). Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures – 2019 Update. Obesity, 27(4), 727-745. https://doi.org/10.1002/oby.22461
 U.S. Food & Drug Administration. (2021). FDA approves new drug treatment for chronic weight management, first since 2014. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014
 Davies, M.J., Bergenstal, R., Bode, B., et al. (2018). Efficacy of Liraglutide for Weight Loss Among Patients with Type 2 Diabetes. JAMA, 314(7), 687-699. https://doi.org/10.1001/jama.2015.9676
 Nauck, M.A., & Meier, J.J. (2018). Incretin hormones: Their role in health and disease. Diabetes, Obesity and Metabolism, 20(Suppl. 1), 5-21. https://doi.org/10.1111/dom.13129
 Novo Nordisk. (2021). Ozempic® (semaglutide) injection. Retrieved from https://www.ozempic.com/
 Aminian, A., Zajichek, A., Arterburn, D.E., et al. (2020). Association of Metabolic Surgery with Major Adverse Cardiovascular Outcomes in Patients with Type 2 Diabetes and Obesity. JAMA, 324(13), 1271-1282. https://doi.org/10.1001/jama.2020.14234
 Wilding, J.P.H., Batterham, R.L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183
 Novo Nordisk. (2021). Wegovy™ (semaglutide) injection. Retrieved from https://www.wegovy.com
 Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11-22. https://doi.org/10.1056/NEJMoa1411892
 Kushner, R.F., Calanna, S., Davies, M., et al. (2020). Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity, 28(6), 1050-1061. https://doi.org/10.1002/oby.22794
 Frias, J. P., Nauck, M. A., Van, J., et al. (2021). Efficacy and safety of Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: a 12-week, randomized, placebo-controlled trial. Diabetes, Obesity and Metabolism, 23(2), 375-385. https://doi.org/10.1111/dom.14240
 Coskun, T., Sloop, K. W., Loghin, C., et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism, 18, 3-14. https://doi.org/10.1016/j.molmet.2018.09.009
 Lilly. (2021). Tirzepatide Significantly Reduced A1C and Body Weight in People Living with Type 2 Diabetes in Two Phase 3 Trials of Lilly’s SURPASS Program. Retrieved from https://investor.lilly.com/news-releases/news-release-details/tirzepatide-significantly-reduced-a1c-and-body-weight-people
 DeFronzo, R. A., & Abdul-Ghani, M. (2021). Tirzepatide: A Glucose-dependent Insulinotropic Polypeptide (GIP)/Glucagon-like Peptide-1 (GLP-1) Co-agonist for the Treatment of Type 2 Diabetes. Diabetes, Obesity and Metabolism, 23(4), 888-897. https://doi.org/10.1111/dom.14319